Quoin Pharmaceuticals, Ltd. (QNRX)
| Market Cap | 4.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.64M |
| Shares Out | 987.22K |
| EPS (ttm) | 774.71 |
| PE Ratio | 0.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,384 |
| Open | 5.02 |
| Previous Close | 5.12 |
| Day's Range | 4.75 - 5.29 |
| 52-Week Range | 3.64 - 33.84 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2023 |
About QNRX
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agree... [Read more]
News
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed...
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...
REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study
Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan disea...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
First patient dosed in Quoin's single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy
Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET
ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseas...
Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial
ASHBURN, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dis...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results
ASHBURN, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dis...
Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dis...
Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
ASHBURN, Va., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...
Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
Company's Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results
ASHBURN, Va., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...
Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients
A Multicenter Open Label Study of QRX003 Topical Lotion in Netherton Syndrome Patients Who Are Currently Receiving Systemic Biologic Therapy. A Multicenter Open Label Study of QRX003 Topical Lotion in...
Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study
Three clinical sites are now fully open; final three sites expected to open imminently Three clinical sites are now fully open; final three sites expected to open imminently
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results
Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton Syndrome Expands number of commercial partnerships to eight, covering 60 countries Signs Research Agreement to develop ...
Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th
ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...
Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering
ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering
ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements
Endo affiliate, Paladin Labs, will commercialize Quoin's lead asset for Netherton Syndrome in Canada Endo affiliate, Paladin Labs, will commercialize Quoin's lead asset for Netherton Syndrome in Canad...
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN , July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidi...
Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study
Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 Versus Vehicle Three Arm, Randomized, Double-Blind, Vehicle Controlled Study Will Test Two Doses of QRX003 V...